Sign in
Not yet taking people in United StatesNo phase

PREPUP: A Randomized Trial of Bonvadis® Versus Collagenase Ointment in Diabetic Foot Ulcers

Key facts

Who runs it
Oneness Biotech Co., Ltd.
Where
Akron, Brooklyn, Circleville, Metairie, Monroeville, North Port, Palm Coast, Philadelphia, South Miami, and Tulsa, United StatesSee the 10 sites
Trial code
Status
Not yet recruiting
People taking part
100 people, planned
Started
Aug 2026
Expected to end
Sept 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Bonvadis® (NWBOT)
  • Clostridial Collagenase Ointment
Record updated
21 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Adults aged ≥18 years with Type 1 or Type 2 diabetes mellitus
  • Presence of at least one diabetic foot ulcer with limited granulation tissue
  • Target ulcer located on the foot, predominantly below the malleolus and not on the dorsal toes
  • Adequate perfusion of the affected limb as confirmed by vascular assessment
  • If multiple eligible ulcers are present, the largest qualifying ulcer will be designated as the target ulcer
  • Willing to comply with the prescribed offloading method and required weekly study visits
  • Willing and able to provide informed consent and comply with study procedures

Who cannot take part

  • Use of immunosuppressive, cytotoxic, biologic, or other medications expected to interfere with wound healing
  • Prior partial amputation, foot deformity, or other foot condition that prevents adequate offloading of the target ulcer
  • Participation in another interventional clinical trial involving an investigational product within the previous 30 days
  • Target ulcer is not diabetic in origin or has exposed tendon or bone
  • Clinically significant ulcer-related complications that, in the investigator's judgment, would interfere with study participation or wound assessment
  • Recent topical steroid use on the target ulcer
  • Pregnancy, planned pregnancy during the study period, or another significant medical condition requiring ongoing supportive treatment
  • Any medical, psychological, nutritional, or hypersensitivity condition that, in the investigator's judgment, may interfere with study participation, assessments, or treatment, including malnutrition or known/suspected hypersensitivity to collagenase or Bonvadis/NWBOT ingredients

Where in United States

  • Akron, OhioHospital not named in the registryNot yet recruiting
  • Brooklyn, New YorkHospital not named in the registryNot yet recruiting
  • Circleville, OhioHospital not named in the registryNot yet recruiting
  • Metairie, LouisianaHospital not named in the registryNot yet recruiting
  • Monroeville, PennsylvaniaHospital not named in the registryNot yet recruiting
  • North Port, FloridaHospital not named in the registryNot yet recruiting
  • Palm Coast, FloridaHospital not named in the registryNot yet recruiting
  • Philadelphia, PennsylvaniaHospital not named in the registryNot yet recruiting
  • South Miami, FloridaHospital not named in the registryNot yet recruiting
  • Tulsa, OklahomaHospital not named in the registryNot yet recruiting

About the trial

What the trial wants to find out

This study is designed to evaluate topical wound products for DFUs using a hybrid design that combines prospectively randomized treatment arms with external control cohorts.

The 2 groups in the trial

  • Bonvadis® (NWBOT)Treatment being tested

    Eligible subjects will be assigned to receive Bonvadis® (NWBOT) plus Standard of Care.

  • Clostridial Collagenase OintmentExisting treatment, for comparison

    Eligible subjects will be assigned to receive Clostridial Collagenase Ointment plus Standard of Care.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Prospective, Multicenter, Multi-Product, Comparative Effectiveness, Randomized Controlled Clinical Trial Evaluating a Novel Wound Bed Optimization Technology (NWBOT) and Standard of Care (SOC) Versus Clostridial Collagenase Ointment (CCO) Plus SOC in Diabetic Foot Ulcers, With Matched-Control Comparison to Topical Hydrogel and Comparisons to Synthetic Standard-of-Care and Topical Collagen Comparator Cohorts.
Record updated
21 August 2026